Beam Therapeutics Inc (NASDAQ: BEAM) kicked off on Tuesday, up 4.65% from the previous trading day, before settling in for the closing price of $23.44. Over the past 52 weeks, BEAM has traded in a range of $20.84-$49.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 54121.88% over the past five years. While this was happening, its average annual earnings per share was recorded -174.10%. With a float of $72.58 million, this company’s outstanding shares have now reached $82.56 million.
Let’s look at the performance matrix of the company that is accounted for 436 employees. In terms of profitability, gross margin is 93.75%, operating margin of -52.25%, and the pretax margin is -40.67%.
Beam Therapeutics Inc (BEAM) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Beam Therapeutics Inc is 12.35%, while institutional ownership is 81.95%. The most recent insider transaction that took place on Jan 02 ’25, was worth 30,628. In this transaction Chief Legal Officer of this company sold 1,241 shares at a rate of $24.68, taking the stock ownership to the 102,968 shares. Before that another transaction happened on Jan 02 ’25, when Company’s SVP, Finance and Treasurer sold 1,117 for $24.68, making the entire transaction worth $27,568. This insider now owns 43,814 shares in total.
Beam Therapeutics Inc (BEAM) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -174.10% per share during the next fiscal year.
Beam Therapeutics Inc (NASDAQ: BEAM) Trading Performance Indicators
Take a look at Beam Therapeutics Inc’s (BEAM) current performance indicators. Last quarter, stock had a quick ratio of 5.69. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.81.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.76, a number that is poised to hit -1.27 in the next quarter and is forecasted to reach -4.79 in one year’s time.
Technical Analysis of Beam Therapeutics Inc (BEAM)
Beam Therapeutics Inc (NASDAQ: BEAM) saw its 5-day average volume 1.35 million, a positive change from its year-to-date volume of 1.34 million. As of the previous 9 days, the stock’s Stochastic %D was 22.13%. Additionally, its Average True Range was 1.75.
During the past 100 days, Beam Therapeutics Inc’s (BEAM) raw stochastic average was set at 30.43%, which indicates a significant decrease from 34.47% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 55.72% in the past 14 days, which was lower than the 66.87% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $26.47, while its 200-day Moving Average is $25.21. Nevertheless, the first resistance level for the watch stands at $24.91 in the near term. At $25.29, the stock is likely to face the second major resistance level. The third major resistance level sits at $25.97. If the price goes on to break the first support level at $23.84, it is likely to go to the next support level at $23.16. The third support level lies at $22.78 if the price breaches the second support level.
Beam Therapeutics Inc (NASDAQ: BEAM) Key Stats
The company with the Market Capitalisation of 2.03 billion has total of 82,806K Shares Outstanding. Its annual sales at the moment are 377,710 K in contrast with the sum of -132,530 K annual income. Company’s last quarter sales were recorded 14,270 K and last quarter income was -96,670 K.
